Show simple item record

Modulation of the neurofibromatosis type 1 gene product, neurofibromin, during Schwann cell differentiation

dc.contributor.authorGutmann, D. H.en_US
dc.contributor.authorTennekoon, Gihan I.en_US
dc.contributor.authorCole, Jeffrey L.en_US
dc.contributor.authorCollins, Francis S.en_US
dc.contributor.authorRutkowski, J. Lynnen_US
dc.date.accessioned2007-04-06T18:41:02Z
dc.date.available2007-04-06T18:41:02Z
dc.date.issued1993-10-01en_US
dc.identifier.citationGutmann, D. H.; Tennekoon, G. I.; Cole, J. L.; Collins, F. S.; Rutkowski, J. L. (1993)."Modulation of the neurofibromatosis type 1 gene product, neurofibromin, during Schwann cell differentiation." Journal of Neuroscience Research 36(2): 216-223. <http://hdl.handle.net/2027.42/50227>en_US
dc.identifier.issn0360-4012en_US
dc.identifier.issn1097-4547en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/50227
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=7505343&dopt=citationen_US
dc.description.abstractNeurofibromin, the product of the neurofibromatosis type 1 (NF1) gene, is a ∼250 kDa protein expressed predominantly in cortical neurons and oligodendrocytes in the central nervous system (CNS) and sensory neurons and Schwann cells in the peripheral nervous system (PNS). To gain insight into the biological role of neurofibromin in Schwann cells, the modulation of NF1 gene expression in a Schwann cell line (MT 4 H1) stimulated to either proliferate or differentiate in response to agents that elevate intracellular cAMP was examined. Untreated cells and cells exposed to mitogenic doses of forskolin (1–10 ΜM) or 8-bromo-cAMP (0.1 mM) expressed low levels of NF1 MRNA and the protein was barely detectable. High doses of forskolin (100 ΜM) or 8-bromo-cAMP (1 mM) induced the expression of both myelin P 0 protein and neurofibromin with an identical time course. Although NF1 mRNA levels peaked within 1–6 hr, the rise in neurofibromin was not apparent until 24–48 hr and peaked 72 hr after treatment. P 0 and neurofibromin were also coinduced by cell-cell contact in high density, untreated cultures. Moreover, differentiation initiated by either cAMP stimulation or high density culture conditions was associated with predominant expression of the type 2 NF1 mRNA isoform. In contrast, type 1 NF1 mRNA isoform expression was observed in untreated Schwann cells or those stimulated with mitogenic doses of forskolin or 8-bromo-cAMP. A switch from the type 1 neurofibromin that can efficiently down-regulate p21-ras to the type 2 isoform with reduced activity may facilitate a p21-ras signaling pathway associated with Schwann cell difrerentiation. © 1993 Wiley-Liss, Inc.en_US
dc.format.extent822589 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherLife and Medical Sciencesen_US
dc.subject.otherNeuroscience, Neurology and Psychiatryen_US
dc.titleModulation of the neurofibromatosis type 1 gene product, neurofibromin, during Schwann cell differentiationen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMolecular, Cellular and Developmental Biologyen_US
dc.subject.hlbsecondlevelNeurosciencesen_US
dc.subject.hlbsecondlevelPsychologyen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelSocial Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartments of Neurology, University of Michigan Medical Center, Ann Arbor ; Departments of Internal Medicine, University of Michigan Medical Center, Ann Arbor ; Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arbor ; 4570 MSRB 2, Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109-0650en_US
dc.contributor.affiliationumDepartments of Pediatrics, University of Michigan Medical Center, Ann Arboren_US
dc.contributor.affiliationumDepartments of Internal Medicine, University of Michigan Medical Center, Ann Arbor ; Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arboren_US
dc.contributor.affiliationumDepartments of Human Genetics, University of Michigan Medical Center, Ann Arbor ; Departments of Internal Medicine, University of Michigan Medical Center, Ann Arbor ; Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arboren_US
dc.contributor.affiliationumDepartments of Pediatrics, University of Michigan Medical Center, Ann Arboren_US
dc.identifier.pmid7505343en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/50227/1/490360212_ftp.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1002/jnr.490360212en_US
dc.identifier.sourceJournal of Neuroscience Researchen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.